Atossa Therapeutics (GB:0HJ7)

Atossa Therapeutics (0HJ7) Share Price & Analysis





What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 16, 2023 which is in 72 days.
    How were Atossa Therapeutics’s earnings last quarter?
    Atossa Therapeutics released its earnings results on May 15, 2023. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.06 by $0.01.
      Is Atossa Therapeutics overvalued?
      According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Atossa Therapeutics pay dividends?
        Atossa Therapeutics does not currently pay dividends.
        What is Atossa Therapeutics’s EPS estimate?
        Atossa Therapeutics’s EPS estimate is -$0.06.
          How many shares outstanding does Atossa Therapeutics have?
          Atossa Therapeutics has 126,624,110 shares outstanding.
            What happened to Atossa Therapeutics’s price movement after its last earnings report?
            Atossa Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.06. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Atossa Therapeutics?
              Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.


                Atossa Therapeutics Stock Smart Score

                The Atossa Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Atossa Therapeutics

                Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Atossa Therapeutics
                Bio-Path Holdings
                Aptose Biosciences
                Zynerba Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis